Dergiler / Medicine Science / 2021 / Cilt: 10 - Sayı: 2

Pharmacological treatment of obesity in clinical practice

Sayfa
651–657
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

If weight loss is inadequate (

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Anti-obesity medications may be considered in the subjects with BMI ≥30 kg/m2, or with BMI 27-29.9 kg/m2 and weight-related comorbidities, whom weight reduction is not achieved via lifestyle modifications alone.
📊
Temel Bulgular & Veri:Anti-obesity medications may be considered in the subjects with BMI ≥30 kg/m2, or with BMI 27-29.9 kg/m2 and weight-related comorbidities, whom weight reduction is not achieved via lifestyle modifications alone.
💡
Sonuç & Katkı:If weight loss is inadequate (
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Anti-obesity medications may be considered in the subjects with BMI ≥30 kg/m2, or with BMI 27-29.9 kg/m2 and weight-related comorbidities, whom weight reduction is not achieved via lifestyle modifications alone. If weight loss is inadequate (

🔖

Bu Makaleye Atıf Yap

Sahin, I., Topaloglu, O. (2022). Pharmacological treatment of obesity in clinical practice. Medicine Science, Cilt: 10 - Sayı: 2, 651–657. https://ajindex.com/articles/579631

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. KSonmez A, Yumuk V, Haymana C, et al. Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study). Obes Facts. 2019;12:167-78. Society of Endocrinology and Metabolism of Turkey. Obesity Diagnosis and Treatment Guideline ISBN: 978-605-4011-31-5.2018;80-6.
  2. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study:a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss andAdverse Events: A Systematic Review and Meta-analysis. JAMA 2016;315:2424. Rosenbaum M, Hirsch J, Gallagher DA, et al. Long-term persistence of adaptive thermogenesis in subjects who havemaintained a reduced body weight. Am J Clin Nutr. 2008;88:906. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8:402-24.
  3. Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and costeffectiveness of using drugs in treating obesepatients in primary care? A systematic review. Health Technol Assess. 2012;16. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin: a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–87.
  4. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–36.
  5. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77. https://www.fda.gov/media/135189/download Access date 14.02.2020.
  6. Bray GA, Tartaglia LA, Bray GA, et al. Medi-cinal strategies in the treatment of obesity. Nature 2000;404:672. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Inte